Literatur
-
1
Yerby M S.
Teratogenic effects of antiepileptic drugs: what do we advise patients?.
Epilepsia.
1997;
38
957-958
-
2 Samrén E B, Lindhout D. Major malformations associated with maternal use of antiepileptic drugs. In: Tomson T, Gram L, Sillanpää M, Johannessen SI (eds) Epilepsy and Pregnancy. Petersfield UK and Bristol PA, USA; Wrightson Biomedical Publishing Ltd 1997: 43-61
-
3 Yerby M R. Pregnancy and teratogenesis. In: Trimble MR (ed) Women and epilepsy. Chichester; Wiley Publisher 1991: 167-192
-
4
Beck-Mannagetta G.
Fehlbildungen und Anomalien, körperliches Wachstum, psychomotorische und intellektuelle Entwicklung.
Epilepsie-Blätter.
1990;
3
1-6
-
5 Finnell R H, Nau H, Yerby M S. Teratogenicity of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs. New York; Raven Press 1995 Fourth edition: 209-230
-
6
Holmes L B, Harvey E A, Coull B A. et al .
The teratogenicity of anticonvulsant drugs.
N Engl J Med.
2001;
344
1132-1138
-
7
Arpino C, Brescianini S, Robert E. et al .
Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE).
Epilepsia.
2000;
41
1436-1443
-
8 Lamotrigine Pregnancy Registry 1 September 1992 through 30 September 2000, executive summery, personal communcation from GlaxoKlineSmith.
-
9
Hernández-Díaz S, Werler M M, Walker A M, Mitchell A A.
Folic acid antagonists during pregnancy and the risk of birth defects.
N Engl J Med.
2000;
43
1608-1614
-
10 Nau H. Towards the mechanism of valproic acid induced neural tube defects. In: Tomson T, Gram L, Sillanpää M, Johannessen SI (eds) Epilepsy and Pregnancy. Petersfield UK and Bristol PA, USA; Wrightson Biomedical Publishing Ltd 1997: 35-42
-
11
Delgado-Escueta A V, Janz D.
Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy.
Neurology.
1992;
42, Suppl 5
149-160
PD Dr. Barbara Tettenborn
Klinik für Neurologie · Kantonsspital St. Gallen
9000 St. Gallen · Schweiz
Email: barbara.tettenborn@kssg.ch
